From January 1, 2024 to March 31, 2024, the company has repurchased 239,555 shares, representing 0.003912% for CNY 10 million. With this, the company has completed the repurchase of 14,351,878 shares, representing 0.23% for CNY 634.67 million under the buyback announced on May 15, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
43.8 CNY | -0.02% | -3.80% | -3.16% |
10:39am | Hengrui Pharma Misses US FDA Approval for Cancer Injection | MT |
09:12am | Hengrui Pharmaceuticals' Unit Gets Nod to Trial SHR-1905 Injection | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.16% | 38.51B | |
+37.87% | 705B | |
+32.82% | 583B | |
-3.72% | 364B | |
+19.74% | 332B | |
+4.89% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+8.77% | 169B |
- Stock Market
- Equities
- 600276 Stock
- News Jiangsu Hengrui Medicine Co., Ltd.
- Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.